<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000996</url>
  </required_header>
  <id_info>
    <org_study_id>VUMC_IRB#201652</org_study_id>
    <secondary_id>R01DK126721</secondary_id>
    <nct_id>NCT05000996</nct_id>
  </id_info>
  <brief_title>Gut Microbiota in Metabolic Surgery</brief_title>
  <official_title>The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g.,&#xD;
      type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly&#xD;
      alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes.&#xD;
      Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its&#xD;
      relation to cardiometabolic health after surgery are limited. Furthermore, few studies have&#xD;
      included African Americans, a population with high rates of cardiometabolic diseases. The&#xD;
      investigators aim to fill these research gaps by establishing a longitudinal, observational&#xD;
      study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or&#xD;
      tissue microbial features related to post-surgery cardiometabolic outcomes. In the current&#xD;
      study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at&#xD;
      Vanderbilt University Medical Center and follow them for up to 10 years after surgery.&#xD;
      Fasting blood and stool samples will be collected at pre-surgery and 3-month and 1-year&#xD;
      post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and&#xD;
      remnants of the stomach) will be collected during operation. Meanwhile, participants will&#xD;
      complete a REDCap survey at baseline and 1-year post-surgery. Participants' electronic&#xD;
      medical records will be used to obtain additional information and facilitate long-term&#xD;
      follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal&#xD;
      microbiome and fecal and blood levels of metabolites and the associations of microbiome and&#xD;
      metabolites with CVD risk score and improvements in hypertension, diabetes, and dyslipidemia&#xD;
      after surgery. This study will advance our understanding of the role of gut microbiota in&#xD;
      metabolic surgery, which may translate into novel approaches to identify and treat obese&#xD;
      patients for better cardiometabolic health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Estimated 10-year risk of atherosclerotic cardiovascular disease</measure>
    <time_frame>From before surgery to 1-year after surgery to 10-year after surgery</time_frame>
    <description>The 10-year risk of atherosclerotic cardiovascular disease based on the American College of Cardiology/American Heart Association pooled cohort equations, incorporating age, sex, race, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, hypertension status, and smoking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>From before surgery to 1-year after surgery to 10-year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From before surgery to 1-year after surgery to 10-year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cholesterol</measure>
    <time_frame>From before surgery to 1-year after surgery to 10-year after surgery</time_frame>
    <description>Total, low-density, and high-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <condition>Morbid Obesity</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool; Blood (plasma, serum, white blood cells, and red blood cells); Tissue (subcutaneous&#xD;
      adipose, omentum, skeletal, jejunum, and stomach)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to enroll 300 patients who undergo metabolic surgery at the Vanderbilt University&#xD;
        Medical Center and follow them up to 10 years after surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical&#xD;
             Center&#xD;
&#xD;
          -  Have a history of type 2 diabetes, hypertension, or dyslipidemia&#xD;
&#xD;
          -  Be able and willing to provide personal information and biological samples needed for&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior gastric operations&#xD;
&#xD;
          -  A history of coronary artery disease, stroke, heart failure, HIV infection, or&#xD;
             untreated viral hepatitis&#xD;
&#xD;
          -  Chemotherapy or radiotherapy for cancer within 2 years&#xD;
&#xD;
          -  Current inflammatory bowel disease or celiac disease&#xD;
&#xD;
          -  Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danxia Yu, PhD</last_name>
    <phone>615-936-7389</phone>
    <email>danxia.yu@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles R Flynn, PhD</last_name>
    <phone>615-343-8329</phone>
    <email>robb.flynn@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt_University MC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danxia Yu, PhD</last_name>
      <phone>615-936-7389</phone>
      <email>danxia.yu@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Britt Biesinger, MPH</last_name>
      <phone>615-421-8055</phone>
      <email>britt.t.biesinger@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yu D, Shu XO, Howard EF, Long J, English WJ, Flynn CR. Fecal metagenomics and metabolomics reveal gut microbial changes after bariatric surgery. Surg Obes Relat Dis. 2020 Nov;16(11):1772-1782. doi: 10.1016/j.soard.2020.06.032. Epub 2020 Jun 27.</citation>
    <PMID>32747219</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Danxia Yu</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05000996/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

